Bertrand Coiffier

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 116:2040-5. 2010
  2. ncbi Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
    Bertrand Coiffier
    Hematology, Centre Hospitalier Lyon Sud, 69310 Pierre Benite, France
    J Clin Oncol 30:631-6. 2012
  3. ncbi Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective
    Bertrand Coiffier
    Hematology Oncology Department, Hospices Civils de Lyon and Université Claude Bernard, Lyon, France
    Oncology (Williston Park) 19:7-15. 2005
  4. ncbi Monoclonal antibodies in the treatment of malignant lymphomas
    Bertrand Coiffier
    Hematology Department, Hospices Civils de Lyon and Claude Bernard University, Pierre-Benite, France
    Adv Exp Med Biol 610:155-76. 2008
  5. ncbi Current strategies for the treatment of diffuse large B cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon, Lyon, France
    Curr Opin Hematol 12:259-65. 2005
  6. ncbi Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Bertrand Coiffier
    Departement d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
    Blood 111:1094-100. 2008
  7. ncbi Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma
    Bertrand Coiffier
    CH Lyon Sud, 69495 Pierre, Benite, France
    Curr Hematol Rep 2:23-9. 2003
  8. ncbi Rituximab therapy in malignant lymphoma
    B Coiffier
    Hematology Department, Hospices Civils de Lyon and Claude Bernard University, Pierre Benite, France
    Oncogene 26:3603-13. 2007
  9. ncbi Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
    Bertrand Coiffier
    Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
    J Clin Oncol 21:4402-6. 2003
  10. ncbi Management of tumor lysis syndrome in adults
    Bertrand Coiffier
    Centre Hospital Lyon Sud, Department of Hematology, 69310 Pierre Benite, France
    Expert Rev Anticancer Ther 7:233-9. 2007

Detail Information

Publications97

  1. ncbi Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 116:2040-5. 2010
    ..The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy...
  2. ncbi Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
    Bertrand Coiffier
    Hematology, Centre Hospitalier Lyon Sud, 69310 Pierre Benite, France
    J Clin Oncol 30:631-6. 2012
    ..The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
  3. ncbi Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective
    Bertrand Coiffier
    Hematology Oncology Department, Hospices Civils de Lyon and Université Claude Bernard, Lyon, France
    Oncology (Williston Park) 19:7-15. 2005
    ..Current studies look at decreasing the. number of patients truly refractory to chemotherapy, decreasing relapse rate with rituximab maintenance, and finding an appropriate regimen for patients with T-cell lymphoma...
  4. ncbi Monoclonal antibodies in the treatment of malignant lymphomas
    Bertrand Coiffier
    Hematology Department, Hospices Civils de Lyon and Claude Bernard University, Pierre-Benite, France
    Adv Exp Med Biol 610:155-76. 2008
  5. ncbi Current strategies for the treatment of diffuse large B cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon, Lyon, France
    Curr Opin Hematol 12:259-65. 2005
    ..This paper reviews the improvement in the treatment of patients with diffuse large B cell lymphoma...
  6. ncbi Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Bertrand Coiffier
    Departement d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
    Blood 111:1094-100. 2008
    ..Preliminary data on safety and objective response are encouraging and support further studies on the role of ofatumumab in CLL patients. This trial was registered at www.clinicaltrials.gov as no. NCT00093314...
  7. ncbi Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma
    Bertrand Coiffier
    CH Lyon Sud, 69495 Pierre, Benite, France
    Curr Hematol Rep 2:23-9. 2003
    ..The putative role of other monoclonal antibodies is discussed...
  8. ncbi Rituximab therapy in malignant lymphoma
    B Coiffier
    Hematology Department, Hospices Civils de Lyon and Claude Bernard University, Pierre Benite, France
    Oncogene 26:3603-13. 2007
    ..Some patients are refractory to rituximab but the precise mechanisms of this refractoriness are not understood...
  9. ncbi Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
    Bertrand Coiffier
    Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
    J Clin Oncol 21:4402-6. 2003
    ..This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy...
  10. ncbi Management of tumor lysis syndrome in adults
    Bertrand Coiffier
    Centre Hospital Lyon Sud, Department of Hematology, 69310 Pierre Benite, France
    Expert Rev Anticancer Ther 7:233-9. 2007
    ..This review provides an overview of rasburicase development and discusses the impact of rasburicase in the prevention and management of TLS...
  11. ncbi Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis
    Bertrand Coiffier
    Hospices Civils de Lyon, Lyon, France
    Cancer Invest 24:548-52. 2006
    ..Hepatitis C virus is usually not associated with reactivation and prophylaxis should not be used...
  12. ncbi Monoclonal antibody as therapy for malignant lymphomas
    Bertrand Coiffier
    Service d Hematologie, Hospices Civils de Lyon et Université Claude Bernard, Lyon 1, CH Lyon Sud, 69495 Pierre Benite, France
    C R Biol 329:241-54. 2006
    ..A combination of rituximab plus chemotherapy, R-CHOP, has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. The role of radio-labelled antibodies is still to be defined...
  13. ncbi First-line treatment of follicular lymphoma in the era of monoclonal antibodies
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Claude Bernard, Centre Hospitalier Lyon Sud, 69495, Pierre Benite, France
    Clin Adv Hematol Oncol 3:484-91, 505. 2005
    ..Also yet to be described is the place of radioimmunotherapy versus rituximab plus chemotherapy. High-dose therapies with autologous stem-cell transplant have a place in the treatment of these patients but not in first line...
  14. ncbi State-of-the-art therapeutics: diffuse large B-cell lymphoma
    Bertrand Coiffier
    Hematology Department, CH Lyon Sud, 69495 Pierre Benite, France
    J Clin Oncol 23:6387-93. 2005
    ..However, much work has to be done for patients with high-risk lymphoma. It may come with a better definition of genetic abnormalities specifically associated with refractoriness to chemotherapy...
  15. ncbi Treatment of non-Hodgkin's lymphoma: a look over the past decade
    Bertrand Coiffier
    Universite Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 7:S7-13. 2006
    ..Although little is known for other indolent lymphomas and mantle cell lymphoma, progress has been made there, too. Several questions remain for future randomized studies to continue our search toward cure...
  16. ncbi Treatment of diffuse large B-cell lymphoma
    Bertrand Coiffier
    Hematology Department, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, Lyon, France
    Curr Hematol Rep 4:7-14. 2005
    ..Current treatment is based on the combination of chemotherapy including cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) or dose-intense CHOP-like regimen, and rituximab (R-CHOP)...
  17. ncbi Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
    Bertrand Coiffier
    Hematology Department, Hospices Civils de Lyon, Pierre Benite, France
    Leuk Lymphoma 50:1916-30. 2009
    ..Overall, the clinical findings to date strengthen mTOR inhibition as a novel and promising strategy for the treatment of certain hematologic malignancies, particularly for MCL...
  18. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  19. ncbi Diffuse large cell lymphoma
    B Coiffier
    Hematology Service, Hospices Civils de Lyon, Lyon, France
    Curr Opin Oncol 13:325-34. 2001
    ..This heterogeneity is probably secondary to the fact that a large proportion of lymphomas seems to occur from a transformation of an unknown indolent lymphoma...
  20. ncbi Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma
    Bertrand Coiffier
    Haematology Department, Hospices Civils de Lyon, Universite Claude Bernard, CH Lyon Sud, Pierre Benite Cedex, France
    Blood Rev 17:25-31. 2003
    ..A lot of questions needs to be answered before the best setting of these drugs will be known...
  21. ncbi Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte
    B Coiffier
    Hospices Civils de Lyon, France
    Ann Oncol 10:1191-7. 1999
    ....
  22. ncbi Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey
    B Coiffier
    Department of Hematology, Hospices Civils de Lyon, CH Lyon Sud, 69495 Pierre Benite Cedex, France
    Eur J Cancer 37:1617-23. 2001
    ..By early identification of patients at the highest risk of developing anaemia, interventions such as epoetin alfa can be employed to reduce or eliminate the need for transfusions...
  23. ncbi Treatment paradigms in aggressive non-Hodgkin's lymphoma in elderly patients
    Bertrand Coiffier
    Hematology Department, Hospices Civils de Lyon, France
    Clin Lymphoma 3:S12-8. 2002
    ..Rituximab added to the CHOP regimen has recently been shown to dramatically improve the survival of these older patients without increasing the toxicity of the treatment...
  24. ncbi Positron emission tomography and gallium metabolic imaging in lymphoma
    B Coiffier
    Hospices Civils de Lyon and Université Claude Bernard, CH Lyon Sud, 69495 Pierre Benite Cedex, France
    Curr Oncol Rep 3:266-70. 2001
    ..Whether this examination will allow for intensified treatment and possible cure of more patients is yet to be demonstrated...
  25. ncbi The impact and management of anaemia in haematological malignancies
    B Coiffier
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Med Oncol 17:S2-10. 2000
    ..Consideration of the detrimental effects of anaemia on cancer patients' physical and emotional well-being and therapeutic outcome suggests that rHuEPO therapy has the potential to provide substantial clinical benefits...
  26. ncbi Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index
    Ewa Lech-Maranda
    Equipe Pathologie des Cellules Lymphoïdes, UMR CNRS 5239, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 58:131-41. 2010
    ..This model may help to identify patients in a given IPI risk group for whom more accurate and risk-adapted treatment could be advised...
  27. ncbi Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients
    Catherine Thieblemont
    Hematology Department, Centre Hospitalier Lyon Sud, , France
    Clin Lymphoma 3:41-7. 2002
    ..We conclude that splenectomy is an efficient treatment for splenic MZL, but that it may be delayed until the occurrence of symptoms or cytopenia...
  28. ncbi Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome
    Jean François Larouche
    Service d Hematologie, Centre Hospitalier Lyon Sud, 69310 Pierre Benite, France
    J Clin Oncol 28:2094-100. 2010
    ..Biopsy at relapse is essential because some patients relapse with indolent histology...
  29. ncbi Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
    Emmanuel Bachy
    Service d Hematologie, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    J Clin Oncol 28:822-9. 2010
    ..Therefore, response-adapted therapy aiming to achieve a CR should be considered as first-line treatment...
  30. ncbi Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    Herve Tilly
    Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
    Blood 102:4284-9. 2003
    ..004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival...
  31. ncbi Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud
    Bernard Lemieux
    Hematology Department, Hospices Civils de Lyon, , Pierre-Benite, France
    Hematol J 5:467-71. 2004
    ..3 months, P = 0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab...
  32. ncbi Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 8:356-8. 2008
    ..Herein, we briefly review the spectrum of immunodeficiency-associated lymphoproliferative disorders (LPDs), discuss the immune deficit induced by rituximab, and speculate on its possible association with EBV reactivation in this patient...
  33. ncbi Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study
    Charles Dumontet
    Hematology Department, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Br J Haematol 118:210-7. 2002
    ..Clinical and biological parameters available at diagnosis can help physicians identify patients with aggressive lymphoma at low or high risk of early death...
  34. ncbi Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon, Lyon, France
    Leuk Lymphoma 51:399-405. 2010
    ..Relapse occurring after rituximab-containing therapy appears to be more aggressive than that occurring after chemotherapy alone. The outcome of retreatment, in terms of progression-free survival, is similar to that of primary treatment...
  35. ncbi CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases
    Lucile Baseggio
    Laboratoire d Hématologie Cellulaire Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon
    Haematologica 95:604-12. 2010
    ....
  36. ncbi Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis
    Herve Ghesquieres
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie, France
    J Clin Oncol 24:5234-41. 2006
    ..The characteristics and prognosis of these particular DLBCL are not well known...
  37. ncbi Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study
    Bertrand Coiffier
    Departement d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France bertrand
    Br J Haematol 150:58-71. 2010
    ..This association still remained statistically significant even when adjusting for relevant baseline covariates including tumour burden...
  38. ncbi Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001
    Catherine Thieblemont
    Hematology Department, Hospices Civils de Lyon Claude Bernard University 69495 Pierre Benite, France
    Leuk Lymphoma 44:257-62. 2003
    ..Considering the natural bias of a retrospective analysis, surgery or chemotherapy was associated with a similar outcome in patients with MALT lymphoma after antibiotics failure...
  39. ncbi Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
    Catherine Thieblemont
    Service d Hematologie Clinique, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Cancer 104:1434-41. 2005
    ..The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high-dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL)...
  40. ncbi Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma
    Christelle Lenain
    Department of Haematology, , Lyon, France
    Hematol J 5:403-9. 2004
    ..A minority of patients with NHL recurrence after a first transplant can be cured by a second course of myeloablative chemotherapy at the cost however of high-risk toxic death...
  41. ncbi Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study
    Catherine Sebban
    Centre Leon Berard, Lyon, France
    J Clin Oncol 26:3614-20. 2008
    ..The effect of these two strategies on the outcome of relapsing patients with follicular lymphoma has never been compared...
  42. ncbi Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL)
    Catherine Thieblemont
    Hematology Departement, Hospices Civils de Lyon, Claude Bernard University, 69495 Pierre Benite, France
    Leuk Lymphoma 45:711-4. 2004
    ..In conclusion, maintenance alemtuzumab therapy seems to increase the time to progression and the survival, without adding hematological toxicities and infectious complications. More patients are needed to confirm this observation...
  43. ncbi Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis
    Catherine Thieblemont
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Blood 103:2727-37. 2004
    ..This study demonstrates that SLL, splenic MZL, and MCL possess specific transcriptional profiles that may be relevant to the pathogenesis and the diagnosis of these histologic subtypes...
  44. ncbi Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients
    Florence Lachenal
    Hospices Civils de Lyon, Department of Internal Medicine, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Medicine (Baltimore) 86:282-92. 2007
    ..The current study underlines the diversity of presenting manifestations of angioimmunoblastic T-cell lymphoma...
  45. ncbi Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
    Catherine Thieblemont
    Haematology Department, Centre Hospitalier Lyon Sud, Pierre, , France
    Lancet Oncol 4:95-103. 2003
    ..Splenectomy is considered the first-line treatment of choice for splenic MZL; it results in only partial remission, but responses are generally sufficient for correcting cytopenia, improving quality of life, and increasing survival...
  46. ncbi Aggressive lymphoma: improving treatment outcome with rituximab
    Bertrand Coiffier
    Hospices Civils de Lyon, Lyon, France
    Anticancer Drugs 13:S43-50. 2002
    ....
  47. ncbi Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases
    Alexandra Traverse-Glehen
    Hospices Civils de Lyon, Service d Anatomie Pathologique, Centre Hospitalier Lyon Sud, Universite Lyon 1, Pierre Benite, France UMR CNRS 5239 Equipe Pathologie des Cellules Lymphoides, Pierre Benite, France
    Histopathology 62:876-93. 2013
    ..To describe 76 cases of splenic marginal zone lymphoma (SMZL), including correlations with clinical and other characteristics...
  48. ncbi Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma
    Bertrand Coiffier
    , Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, , Lyon, France
    Semin Oncol 31:7-11. 2004
    ..The development of newer treatment strategies incorporating rituximab may improve the cure rate further...
  49. ncbi Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
    Jehan Dupuis
    Department of Hematology, , , France
    Blood 108:4163-9. 2006
    ..These results warrant further studies regarding pathogenesis and specific treatment approaches for EBV-associated PTCL patients...
  50. ncbi Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly
    Bertrand Coiffier
    , Lyon, France
    Semin Oncol 30:21-7. 2003
    ..This article reviews the activity of rituximab in aggressive lymphoma and highlights its potential in both previously untreated and relapsed disease...
  51. ncbi Rituximab in the treatment of diffuse large B-cell lymphomas
    Bertrand Coiffier
    , Lyon, France
    Semin Oncol 29:30-5. 2002
    ..The toxic events observed with the combination were not more numerous or severe than those observed with CHOP alone. Rituximab is a chimeric anti-CD20 antibody that increases the treatment options in patients with B-cell lymphomas...
  52. ncbi Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
    Adrien Chauchet
    Department of Hematology, Centre Hospitalier Universitaire Lyon Sud, Pierre Benite, France
    J Hematol Oncol 5:27. 2012
    ..Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors...
  53. ncbi Standard treatment of advanced-stage diffuse large B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Claude Bernard, Lyon, France
    Semin Hematol 43:213-20. 2006
    ..Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented...
  54. ncbi Nongastric mucosa-associated lymphoid tissue lymphomas
    Catherine Thieblemont
    Hematology Department, Hospices Civils de Lyon, , Lyon, France
    Clin Lymphoma 3:212-24. 2003
    ..For disseminated disease, treatment recommendations include chemotherapy with fludarabine or chlorambucil or chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) in cases of large tumor mass..
  55. ncbi Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Blood 111:2253-60. 2008
    ..These results, as well as the clinical evolution, show that those lymphoma cases represent a homogeneous group distinct from SMZL and reminiscent of hairy cell leukemia variant, perhaps corresponding to a separate lymphoma entity...
  56. ncbi Lymphoma in older patients
    Catherine Thieblemont
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie Clinique, Pierre Benite, France
    J Clin Oncol 25:1916-23. 2007
    ..Patients older than 80 years may also be treated with rituximab plus CHOP, except for those having severe organ failure secondary to other diseases. Very few of these older patients may benefit from a salvage treatment after relapse...
  57. ncbi Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas
    Florence Broussais Guillaumot
    Department of Hematology, Hospices Civils de Lyon and Université Lyon I, Lyon, France
    Clin Lymphoma Myeloma 8:S50-6. 2007
    ..The future benefit for patients with adverse prognostic parameters might not come from dose-dense or dose-intense CHOP-like regimens but from the addition of another drug to R-CHOP...
  58. ncbi Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France
    Pascal Seve
    Department of Internal Medicine, Lyon Civil Hospices, Lyon, France
    Eur J Gastroenterol Hepatol 16:1361-5. 2004
    ..We sought to determine whether such an association could be found in patients treated in the Rhone-Alpes region in south-east France. Our main interest was to identify histological subtypes preferentially linked to HCV...
  59. ncbi Cytogenetic and molecular analysis of 12 cases of primary cutaneous marginal zone lymphomas
    Arnaud de la Fouchardiere
    , Centre Hospitalier Lyon Sud, , France
    Am J Dermatopathol 28:287-92. 2006
    ..These data also underline that fluorescence in situ analysis on routine skin punch biopsies represents a reliable tool for the detection of chromosomal changes, but requires consistent dermal infiltration...
  60. ncbi Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 61:165-74. 2013
    ..VEGF may be a useful marker for selecting the patients for whom new treatment approaches, especially those based on VEGF inhibitors, could be recommended...
  61. ncbi Maintenance therapy in diffuse large B-cell lymphoma
    Anne Sophie Michallet
    Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Curr Opin Oncol 24:461-5. 2012
    ..In this article, we focused on the role of maintenance therapy in diffuse large B-cell lymphoma (DLBCL)...
  62. ncbi Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France
    Discov Med 13:253-65. 2012
    ..This review will report literature data and discuss the differential diagnosis, particularly with HCL-V...
  63. ncbi Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies
    Fadela Bouafia
    , Centre Hospitalier Lyon Sud, Chemin du Grand Revoyet, , France
    Bull Cancer 91:E229-40. 2004
    ..We conclude that there are characteristic alterations in serum LDH profiles in patients with haematopoietic malignancies and that some of these may be more interesting in terms of prognostic value than total serum LDH...
  64. ncbi Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Gilles Salles
    Hospices Civils de Lyon, Universite Claude Bernard, UMR CNRS5239, Pierre Benite, France
    Lancet 377:42-51. 2011
    ..We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen...
  65. ncbi Recent developments in the treatment of aggressive non-Hodgkin lymphoma
    Anne Sophie Michallet
    Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
    Blood Rev 23:11-23. 2009
    ..Effective delivery of dose-dense regimens requires granulocyte colony-stimulating factor support, which should also be considered for standard CHOP. A key question for the future is whether R-CHOP-14 is superior to R-CHOP-21...
  66. ncbi Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil 3737 Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Blood 103:3529-34. 2004
    ..76, P =.00035) and OS (RR =.78, P =.0015). These results indicate that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon involves a substantial genetic component...
  67. ncbi Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    , , Lyon, France
    Eur Cytokine Netw 17:60-6. 2006
    ..The plasma concentration of IL-10 may be a useful marker for evaluation of disease activity...
  68. ncbi Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Bertrand Coiffier
    Hematology, Hospices Civils de Lyon, Lyon, France
    Lancet Oncol 12:773-84. 2011
    ..We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting...
  69. ncbi Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma
    Catherine Thieblemont
    , Lyon, France
    Int J Hematol 76:394-400. 2002
    ..Many questions must be answered before the best setting for MoAbs in the treatment of lymphoma patients can be determined...
  70. ncbi Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma
    Sophie Gazzo
    , Centre Hospitalier Lyon Sud, , Lyon, France
    Haematologica 88:31-8. 2003
    ....
  71. ncbi Groshong or implanted catheter infections in ambulatory haematological patients
    Raphaelle Girard
    Hygiene and Epidemiology Unit, Centre Hospitalier Lyon Sud, Pierre Benite, France
    J Infect Public Health 3:134-41. 2010
    ..These results, consistent with other studies, are not only useful in validating prevention policy but also in demonstrating lack of catheter traceability...
  72. ncbi Maintenance therapy in follicular lymphoma
    Anne Sophie Michallet
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, Lyon, France
    Curr Opin Oncol 23:449-54. 2011
    ..This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma...
  73. ncbi A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma
    Charles Dumontet
    Service d Hematologie, CH Lyon Sud, Pierre Benite, Laboratoire d Hematologie, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003 Lyon Cedex 03, France
    Bull Cancer 93:E115-8. 2006
    ..The overall response rate was 58 % with a median duration of response of 12 months. Miltefosine is a safe, simple and effective treatment in certain patients with cutaneous T-cell lymphoma...
  74. ncbi Rituximab in diffuse large B-cell lymphoma
    Bertrand Coiffier
    , Lyon, France
    Clin Adv Hematol Oncol 2:156-7. 2004
  75. ncbi Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review
    Bertrand Coiffier
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    J Clin Oncol 26:2767-78. 2008
    ..Standardized guidelines, however, are needed to aid in the stratification of patients according to risk and to establish prophylaxis and treatment recommendations for patients at risk or with established TLS...
  76. ncbi Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma
    Bertrand Coiffier
    , Centre Hospitalier Lyon-Sud, France
    Tumori 88:S26-8. 2002
  77. ncbi [Pathological and clinical correlations in primary cutaneous B-cell lymphomas: a series of 44 cases]
    Arnaud de la Fouchardiere
    Service d Anatomie Pathologique, Hopital Croix Rousse, Lyon
    Ann Pathol 25:8-17. 2005
    ..histological and clinical relationship study of 44 cases of primary cutaneous B cell lymphoma, classified according to WHO classification...
  78. ncbi Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma
    Bertrand Coiffier
    , Centre Hospitalier Lyon-Sud, Cedex, France
    Semin Oncol 29:18-22. 2002
    ..These groundbreaking data are the first in 20 years to show statistical improvement over CHOP and this suggests that rituximab plus CHOP may become the new gold standard treatment for elderly patients with DLCL...
  79. ncbi Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma
    Christian Gisselbrecht
    Institut d Hematologie, GELA Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Clin Oncol 20:2472-9. 2002
    ....
  80. ncbi Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma
    Bertrand Coiffier
    Blood 104:1584-5; author reply 1585-6. 2004
  81. ncbi Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Nicolas Mounier
    Service d Onco Hématologie, INSERM ERM0220 Hôpital Saint Louis, AP HP, Paris, France
    Blood 101:4279-84. 2003
    ..These results suggest that rituximab is able to prevent chemotherapy failure in patients with bcl-2 protein overexpression...
  82. ncbi ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
    Felix Reyes
    Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Creteil, France
    N Engl J Med 352:1197-205. 2005
    ..To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone...
  83. ncbi AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy
    Nicolas Mounier
    Institut Universitaire d Hématologie GELA, INSERM U728 Hôpital Saint Louis AP HP 1, avenue Claude Vellefaux, 75010 Paris, France
    Blood 107:3832-40. 2006
    ..5, P < .001) but not chemotherapy regimen. Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy...
  84. ncbi Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Blood 108:2540-4. 2006
    ..After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients...
  85. ncbi Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma
    Jacek Nowak
    Institute of Haematology and Blood Transfusion, Warsaw, Poland
    Genes Chromosomes Cancer 46:500-7. 2007
    ..We conclude that 8.1 AH is an important contributor to NHL outcome. In contrast to A*01-B*08-TNF(-308A, the remaining alleles (Cw*07, DRB1*03, LTA+252G) associated with the 8.1 AH seem to be its passive components...
  86. ncbi A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
    Julie M Vose
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 48:39-45. 2007
    ..Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies...
  87. ncbi Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
    Richard I Fisher
    James P. Wilmot Cancer Center, University of Rochester, NY, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Recent and ongoing studies are moving us closer towards that goal...
  88. ncbi Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
    Marc Andre
    Hematology Department, Centre Hospitalier Notre Dame et Reine Fabiola, Grand Rue 3, 6000 Charleroi, Belgium, E mail
    Blood 103:1222-8. 2004
    ..9; P <.001). With a long follow-up, the ACVBP regimen was highly effective for the treatment of aggressive NHL. Increases occurred in secondary MDS/AML and in lung cancer among men...
  89. ncbi Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma
    Nicolas Mounier
    Haematologica 91:715-6. 2006
    ....
  90. ncbi Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production
    Mario Cazzola
    Division of Haematology, University of Pavia Medical School, Pavia, Italy
    Br J Haematol 122:386-93. 2003
    ..Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective...
  91. ncbi Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs
    Caroline Besson
    , , APHP, Paris, France
    J Clin Oncol 24:953-60. 2006
    ..CONCLUSION: HCV-positive patients with DLCL differ from other patients both at presentation and during chemotherapy. Specific protocols evaluating antiviral therapy should be designed for these patients...
  92. ncbi Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
    Nathalie Mourad
    INSERM U728, Paris, France
    Blood 111:4463-70. 2008
    ..It portends a poor prognosis even when treated intensively. However, AITL is not always lethal with 30% of patients alive at 7 years...
  93. ncbi Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
    Bertrand Coiffier
    J Clin Oncol 21:2457-9. 2003
  94. ncbi Dose intensity or monoclonal antibody in first-line treatment
    Bertrand Coiffier
    Centre Hospitalier Lyon-Sud, Pierre Benit, France
    Hematol J 5:S154-8. 2004
  95. ncbi Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survival
    Catherine Thieblemont
    Leuk Lymphoma 49:1403-6. 2008
  96. ncbi Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study
    Miklos Pless
    University Hospital of Basel, Switzerland
    Clin Cancer Res 10:1299-305. 2004
    ..This Phase IIa study reports the findings of SAM486A monotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL)...
  97. ncbi ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
    ..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...